Group 1 - The stock of Green Harmony (688017) has a comprehensive score of 50.59, indicating a strong performance [1] - The main cost analysis shows that the current main cost is 124.11 yuan, with a 5-day average of 122.30 yuan and a 20-day average of 121.55 yuan [1] - Over the past year, the stock has experienced one limit-up and no limit-down events [1] Group 2 - The short-term resistance level is at 126.93 yuan, while the short-term support level is at 116.32 yuan [2] - The mid-term resistance level is at 130.19 yuan, and the mid-term support level is at 115.45 yuan [2] - As of June 26, 2025, the net outflow of main funds was 39.43 million yuan, accounting for 9% of the total transaction volume [2]

政策动向 《采用脑机接口技术的医疗器械非侵入式设备通用技术条件》国家标准立项申请公开征求意见 6月25日，据媒体从国家药品监督管理局医疗器械标准管理中心获悉，全国医用电器标准化技术委员会 医用电子仪器分技术委员会对《采用脑机接口技术的医疗器械非侵入式设备通用技术条件》医疗器械国 家标准立项申请项目公开征求意见。据悉，文件规定了采用脑机接口技术的非侵入式医疗器械采集、解 码、外控设备、接触人体部件的穿戴力学、人机交互可用性的性能指标及测试方法。 本文件适用于采 用脑机接口技术的非侵入式医疗设备。 根据介绍，随着全球化进程的推进，国际间的医疗器械交流和合作日益频繁，制定与国际接轨的标准有 助于促进国际合作；对于监管机构而言，标准化的测试方法可以提高监管效率，减少因标准不统一带来 的监管难度和成本；随着非侵入式神经调控领域的快速发展，会有越来越多的企业投入到相关产品的研 发和生产中。统一的测试方法标准有助于规范产业，促进健康有序的市场竞争。 李利在天津调研支持医药产业研发创新工作 6月25日，国家药监局官微显示，6月23日至25日，国家药监局党组书记、局长李利在天津市走访考察脑 机交互与人机共融海河实验室、天士力医 ...

Asia Pacific Equity Research 23 June 2025 J P M O R G A N This material is neither intended to be distributed to Mainland China investors nor to provide securities investment consultancy services within the territory of Mainland China. This material or any portion hereof may not be reprinted, sold or redistributed without the written consent of J.P. Morgan. China Medtech An eventful Friday: EU procurement ban negative; China government innovation push positive On June 20th, we noted two policy items in the ...

Group 1 - The stock of Aihuilong (688575) has a comprehensive score of 46.93, indicating a weak performance [1] - The main cost analysis shows that the current main cost is 14.81 yuan, with a 5-day main cost of 14.82 yuan and a 20-day main cost of 14.95 yuan [1] - There have been no instances of the stock hitting the upper or lower limits in the past year [1] Group 2 - The short-term pressure level is at 14.71 yuan, while the short-term support level is at 14.49 yuan [2] - The stock price has broken through the short-term pressure level, suggesting a potential short-term strength [2] - On June 25, 2025, the net inflow of main funds was 115.50 thousand yuan, accounting for 3% of the total transaction amount [2]

Group 1 - The stock of Sanyou Medical (688085) has a comprehensive score of 43.15, indicating a weak performance [1] - The main cost analysis shows that the current main cost is 18.74 yuan, with a 5-day main cost of 18.44 yuan and a 20-day main cost of 19.31 yuan [1] - There have been no instances of the stock hitting the upper limit in the past year, and it has also not hit the lower limit [1] Group 2 - The short-term pressure level is at 18.73 yuan, while the short-term support level is at 18.05 yuan [2] - The stock price has broken through the short-term pressure level, indicating a potential short-term strength, although the medium-term trend remains unclear [2] - The funds flow data for June 25, 2025, shows a net outflow of 17.43 million yuan from main funds, with retail investors experiencing a net outflow of 4.39 million yuan [2]

医疗健康ETF泰康紧密跟踪国证公共卫生与医疗健康指数，国证公共卫生与医疗健康指数反映A股市场 中公共卫生与医疗健康产业上市公司的市场表现。 截至2025年6月25日 13:26，医疗健康ETF泰康(159760)多空胶着，盘中溢价频现，跟踪指数国证公共卫 生与医疗健康指数(980016)上涨0.11%，成分股惠泰医疗(688617)上涨3.63%，通化东宝(600867)上涨 2.65%，奕瑞科技(688301)上涨1.80%，特宝生物(688278)上涨1.18%，华润三九(000999)上涨0.89%。 消息面上，6月20日，国家药监局召开会议，研究部署支持高端医疗器械创新发展举措，审议通过《关 于优化全生命周期监管支持高端医疗器械创新发展的举措》，《举措》提出医用机器人、高端医学影像 设备、人工智能医疗器械和新型生物材料医疗器械等技术集成度高，是高端医疗器械的典型产品，也是 塑造医疗器械新质生产力的关键。 信达证券认为，短期回调不改医药生物板块中长期向好趋势，一方面集采优化腾挪创新药价格空间，审 评审批提速推动管线兑现，叠加海外授权交易持续兑现，创新药大趋势未改，另外随着促内需举措逐步 落地，医疗器械、 ...

国家药监局组织召开加强医疗器械网络销售重点产品监测和处置工作调度会。会议通报医疗器械网络销 售重点产品监测处置工作情况，听取北京、上海、浙江、贵州等地医疗器械网络销售监管工作情况，对 进一步加强医疗器械网络销售监管重点进行部署。会议强调，在全面推进网络销售监管的基础上，聚焦 群众和社会关切，强化重点产品监管。坚持线上违法线索和线下违法行为一体查处，坚持网络监测、检 查、抽检、处罚相结合，坚持依法履职、协同治理、闭环处置原则，有效保障公众网购用械安全。 ...

Core Viewpoint - The stock of Hangya Technology (688510) shows a strong overall score of 62.04, indicating a robust performance in the market [1] Group 1: Price and Cost Analysis - The current main cost for the stock is 22.00 yuan, with a 5-day main cost of 21.64 yuan, a 20-day main cost of 20.74 yuan, and a 60-day main cost of 18.71 yuan [1] - The stock has not experienced any limit-up or limit-down events in the past year [1] Group 2: Technical Analysis - Short-term pressure level is at 22.12 yuan, while the short-term support level is at 20.95 yuan [2] - The mid-term pressure level is at 22.32 yuan, and the mid-term support level is at 18.00 yuan [2] - The current short-term and mid-term trends are unclear, awaiting direction from main capital [2] Group 3: Fund Flow Data - On June 24, 2025, the net outflow of main capital was 457.56 million yuan, accounting for -2% of the total transaction volume [2] - There was a net inflow of 483.10 million yuan from large orders, while large orders saw a net outflow of 940.66 million yuan [2] - Retail investors contributed a net inflow of 10.84 million yuan [2] Group 4: Financial Data - The latest financial report indicates earnings per share of 0.12 yuan and an operating profit of 0.36 billion yuan [3] - The sales gross margin stands at 41.234%, with a net profit of 30,860,960.17 yuan [3] Group 5: Related Industries - The stock is associated with various sectors, including aerospace (-0.18%), medical devices (1.81%), large aircraft (1.21%), and general aviation (1.42%) [4]

普门科技688389 时间: 2025年6月24日星期二 39.86分综合得分 偏弱 趋势方向 主力成本分析 12.77 元 当日主力成本 12.59 元 5日主力成本 12.88 元 20日主力成本 13.26 元 60日主力成本 周期内涨跌停 过去一年内该股 短期压力位 12.45 涨停 0次 跌停 0 次 北向资金数据 | 持股量225.77万股 | 占流通比0.52% | | --- | --- | | 昨日净买入4.23万股 | 昨日增仓比0.01% | | 5日增仓比0.122% | 20日增仓比0.15% | 技术面分析 12.77 短期支撑位 13.25 中期压力位 12.45 中期支撑位 目前中期趋势不慎明朗，静待主力资金选择方向 K线形态 暂无特殊形态 资金流数据 2025年06月24日的资金流向数据方面 | 主力资金净流入107.01万元 | | --- | | 占总成交额3% | | 超大单净流入0.00元 | | 大单净流入107.01万元 | | 散户资金净流入96.82万 | 关联行业/概念板块 医疗器械 1.41%、体外诊断 1.09%、深圳特区 2.23%、医疗器械概念 1. ...

心脉医疗688016 时间: 2025年6月24日星期二 46.30分综合得分 偏弱 趋势方向 主力成本分析 87.89 元 当日主力成本 86.73 元 5日主力成本 88.12 元 20日主力成本 87.76 元 60日主力成本 周期内涨跌停 跌停 0 次 北向资金数据 | 持股量91.46万股 | 占流通比0.74% | | --- | --- | | 昨日净买入0.80万股 | 昨日增仓比0.007% | | 5日增仓比0.05% | 20日增仓比-0.197% | 技术面分析 89.05 短期压力位 过去一年内该股 涨停 0次 85.53 短期支撑位 90.92 中期压力位 85.53 中期支撑位 目前短线趋势不慎明朗，静待主力资金选择方向； 目前中期趋势不慎明朗，静待主力资金选择方向 K线形态 暂无特殊形态 资金流数据 2025年06月24日的资金流向数据方面 | 主力资金净流入201.84万元 | | --- | | 占总成交额2% | | 超大单净流入113.01万元 | | 大单净流入88.83万元 | | 散户资金净流入200.81万 | 风险提示：以上内容仅作为作者或者嘉宾的观点，不代表 ...